Erasca 的 KRAS 靶向治疗药物 ERAS-0015 在 EORTC-NCI-AACR 会议上展示初步数据
STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment
Erasca 将在 EORTC-NCI-AACR 会议上展示其 KRAS 靶向治疗药物 ERAS-0015 的初步数据,CEO 表示该药物在第二线及以上胰腺癌中的总体反应率可能达到 40% 左右,这将显著区别于 Revolution Medicines 的 Rasonque。
This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter. Sign up here to get it delivered to your inbox. And subscribe to STAT+ to get an unabridged version, with exclusive content.
Erasca’s pitch is straightforward: The U.S.-based biotech says it went to China and found a more potent, better-tolerated pan-RAS inhibitor than Revolution Medicines’ Rasonque. To date, Erasca has backed up its claim with scant data from an early-stage study disseminated via press releases. The story might be true, it might not be, but for now that’s less important to investors than Erasca’s $5 billion market value, which is a fraction of the $35 billion carried by Revolution Medicines. The valuation disparity makes sense given Revolution’s lead, but it also stokes speculation that Erasca could be an attractive takeover target.
On Friday, the company is presenting another slug of data on its drug, called ERAS-0015, at the EORTC-NCI-AACR “Triple” meeting in Barcelona. Erasca knows what it’s presenting already, obviously, so without breaking the meeting’s embargo policy, CEO Jonathan Lim has been signaling to investors at investment banking conferences that a “4-handle” — Wall Street lingo for 40%-ish — overall response rate from ERAS-0015 in second line-plus pancreatic cancer would be “meaningfully different” from Rasonque.
来源:STAT 主站 · statnews.com